Key result
Full dapagliflozin implementation is projected to cut 1-year mortality by ~17% and reduce HF readmissions.
Why the study?
The projected effectiveness of dapagliflozin in patients with heart failure with reduced ejection fraction in clinical practice in Spain needed estimation.
Does projected implementation of dapagliflozin reduce mortality and heart failure readmission in patients hospitalized for HFrEF in clinical practice?
Cohort (n=1,595)
Yes
Does projected implementation of dapagliflozin reduce mortality and heart failure readmission in patients hospitalized for HFrEF in clinical practice?
Projected implementation of dapagliflozin in real-world HFrEF patients admitted to internal medicine departments could substantially reduce 1-year mortality and heart failure readmissions.
Answers are grounded in this paper and cite their sources.
May support dapagliflozin implementation to lower HFrEF mortality and readmissions; leaves open confirmation in randomized trials.
Aim: To estimate the projected effectiveness of dapagliflozin in subjects with heart failure (HF) with reduced ejection fraction in clinical practice in Spain. Materials & methods: This multicenter cohort study included subjects aged 50 years or older consecutively hospitalized for HF in internal medicine departments in Spain. The projected clinical benefits of dapagliflozin were estimated based on results from the DAPA-HF trial. Results: A total of 1595 patients were enrolled, of whom 1199 (75.2%) were eligible for dapagliflozin. Within 1 year after discharge, 21.6% of patients eligible for dapagliflozin were rehospitalized for HF and 20.5% died. Full implementation of dapagliflozin led to an absolute risk reduction of 3.5% for mortality (number needed to treat = 28) and 6.5% (number needed to treat = 15) for HF readmission. Conclusion: Treatment with dapagliflozin in clinical practice may markedly reduce mortality and readmissions for HF.
No takes yet. Share an insight, caveat, or question.
Montero-Pérez-Barquero et al. (2023) conducted a cohort in Heart failure with reduced ejection fraction (n=1,595). Dapagliflozin (projected) vs. Standard care (observed) was evaluated on All-cause mortality at 1 year (ARR 3.5%). Full implementation of dapagliflozin in clinical practice was projected to yield an absolute risk reduction of 3.5% for mortality and 6.5% for heart failure readmission at 1 year.
Synapse has enriched 10 related papers. Consider them for comparative context: